VivoSeq
Metabolic & Endocrine

Hypoglycemia

66

Pipeline Programs↗

8

Active Trials↗

32

Companies Involved↗

Hypoglycemia is a moderately active landscape with 66 programs across 32 companies. The most active players are Map77, Johnson & Johnson, Otsuka. 18 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

64/100

Pipeline Velocity

6/100

Mech. Concentration

8/100

Completion Rate

74/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Map77

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1Otsuka logo

Otsuka

1 program

Phase 1AbbVie logo

AbbVie

1 program

Phase 1M

MBX Biosciences

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

65 of 76 classified programs — the dominant modality here.

14%ALL OTHERSPeptide1013%Monoclonal antibody11%

Small molecule leads; the ring shows all 76 classified programs, each share of the total. Modality classified for 99% of 78 pipeline programs.

Analysis

Trial Status

87

clinical trials

Completed51 · 59%
Terminated12 · 14%
Unknown status8 · 9%
Withdrawn6 · 7%
Active, not recruiting4 · 5%
Recruiting3 · 3%
Other3 · 3%

Clinical Trials

Trial Activity

87 trials

Restoration of Hypoglycemia Awareness With Metoclopramide
Recruiting·—·Phase 2·NCT03970720·36 enrolled
Canakinumab for the Treatment of Postprandial Hypoglycemia
Recruiting·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT05401578·56 enrolled
Fasting Hypoglycemia: Diagnosis and Treatment
Recruiting·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00001276·1,500 enrolled
GLP-1 and Hypoglycemia
Active, not recruiting·UUniversity of Maryland, Baltimore·Phase 1·NCT01858896·28 enrolled
Liver Glycogen and Hypoglycemia in Humans
Active, not recruiting·—·Phase 1·NCT03241706·40 enrolled
Avexitide for Treatment of Post-Bariatric Hypoglycemia
Active, not recruiting·AAmylyx Pharmaceuticals Inc.·Phase 3·NCT06747468·75 enrolled
Glucagon Dose-Response in Patients With Post-Bariatric Hypoglycemia
Active, not recruiting·JJoslin Diabetes Center·Phase 4·NCT06986603·28 enrolled
Effect of Antenatal Corticosteroids on Neonatal Hypoglycemia
Not yet recruiting·—·N/A·NCT06716918·188 enrolled
A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D
Completed·Zealand Pharma logoZealand Pharma·Phase 3·NCT05378672·8 enrolled
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Completed·JJoslin Diabetes Center·Phase 4·NCT01841359·22 enrolled
The Efficacy of Self-Manufactured 40% Dextrose Gel in Asymptomatic Transient Neonatal Hypoglycemia Treatment
Completed·IIndonesia University·Phase 4·NCT07015450·133 enrolled
Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study
Completed·UUniversity Hospital, Basel, Switzerland·N/A·NCT03200782·12 enrolled
Hypoglycemia Associated Autonomic Failure in Type 1 DM, Q2
Completed·VVanderbilt University·N/A·NCT00592332·56 enrolled
Mechanisms for Restoration of Hypoglycemia Awareness
Completed·YYale University·Phase 1·NCT03738852·55 enrolled
Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia
Completed·ZZosano Pharma Corporation·Phase 1·NCT02459938·16 enrolled
Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)